The Elliot Lewis Center is actively participating in 15-20 multiple sclerosis clinical trials at any given time. Our Center participates in numerous clinical trials related to Multiple Sclerosis treatment. Recent trials have included the new oral agents, Tecfidera and Gilenya, now approved for relapsing remitting MS and Plegridy, the newest injectable medication approved for relapsing remitting MS. Our center also participates in clinical trials with treatments under study and not yet available for relapsing and progressive forms of MS.
For additional information about clinical research at The Elliot Lewis Center, please contact Clinical Research Coordinators, Kelly Luciani and Hannah Geils at 781-591-8313 or 781-591-8314. You can also email them at KellyLuciani@ElliotLewisMS.org or HannahGeils@ElliotLewisMS.org